Core Laboratory Infectious Disease

Infectious Disease — Retrovirus

Contact a Rep HTML

Request more information about Roche's Retrovirus Assay.

Please complete the form below to speak with a Roche representative.

 
 
 
 
Overview

Elecsys® HIV combi PT 4th generation assay

Early diagnosis of HIV infection provides timely access to therapy, which could improve patient outcomes, including quality of life.1

Identify HIV early across groups and subtypes with p24 antigen detection.

Excellent analytical sensitivity of 0.84 ± 0.11 IU/mL

100% clinical sensitivity to HIV-1, recognition of all known HIV groups and subtypes

High specificity in samples from clinical routine, pregnancy and pediatric testing (99.94%)

Excellent reproducibility

HIV continues to impact lives

Don’t let it elude capture.

More than 1.2 million Americans live with HIV.2

40,000 HIV infections are diagnosed in the U.S. every year.2

13% of HIV-infected Americans don’t even know they are infected.2

To learn more about our Elecsys® HIV combi PT assay,
Download the HIV combi PT brochure.

Infectious Disease Portfolio

References:

  1. Early diagnosis of HIV infection: https://www.hiv.va.gov/provider/topics/testing-early-diagnosis.asp(accessed November 30, 2017)
  2. “Trends in U.S. HIV Diagnoses,” 2005–2014, CDC Fact Sheet, February 2016.
Resources

Outside of Pepper mode, this text will be replaced by the resource cards.

Contact Us

Outside of Pepper mode, this text will be replaced by the content added in the above "Contact a Rep HTML" code editor.